Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | F2 | P00734 | 1/20 | 0.30 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.30 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.30 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7638470 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL5374510 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL5365862 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL4924486 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL8380164 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL28212362 | 1.00 | THRB (0.52) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL6892577 | 0.97 | THRB (0.50) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL7630035 | 0.97 | THRB (0.48) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL9218463 | 0.94 | THRB (0.48) | THRBLMNACA2CA1MMP1 | |
| SCHEMBL15012282 | 0.94 | THRB (0.48) | THRBLMNACA2CA1MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12365663-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20240287018-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | CORSAIR PHARMA INC (US) | 2024-08-29 | — | — | US | disclosed |
| US-11958822-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2024-04-16 | — | — | US | disclosed |
| US-20230331691-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. | 2023-10-19 | — | — | US | disclosed |
| EP-4137127-A1 | PRODRUGS OF TREPROSTINIL | Corsair Pharma, Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11505535-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2022-11-22 | — | — | US | disclosed |
| EP-3712142-B1 | PRODRUGS OF TREPROSTINIL | CORSAIR PHARMA INC (US) | 2022-07-06 | — | — | EP | disclosed |
| US-11339139-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220112173-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. (US) | 2022-04-14 | — | — | US | disclosed |
| US-11046666-B2 | Treprostinil derivative compounds and methods of using same | Corsair Pharma, Inc. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20040151779-A1 | Stable flowable protien and nucleic acd formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity | ALZA CORPORATION | 2004-08-05 | — | — | US | disclosed |
| US-6730328-B2 | ACTIVE AGENT CONTAINING POWDER WHEREIN ACTIVE AGENT HYDRATION IS LESS THAN 10%, AND VEHICLE SUCH AS MINERAL OIL, PERFLUORODECALIN, METHOXYFLURANE, TETRADECANE OR PERFLUOROTRIBUTYLAMINE; STORAGE STABILITY, CHEMICAL STABILITY | DURECT CORPORATION | 2004-05-04 | — | — | US | disclosed |
| US-20040082937-A1 | Method and device for the controlled delivery of parathyroid hormone | MICROCHIPS BIOTECH, INC. | 2004-04-29 | — | — | US | disclosed |
| US-20040043042-A1 | Microscale lyophilization and drying methods for the stabilization of molecules | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-03-04 | — | — | US | disclosed |
| EP-0939655-B1 | STABLE PROTEIN AND NUCLEIC ACID FORMULATIONS USING NON-AQUEOUS, ANHYDROUS, APROTIC, HYDROPHOBIC, NON-POLAR VEHICLES WITH LOW REACTIVITY | ALZA CORP (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20010038859-A1 | Stable protein and nucleic acid formulations using non-aqueous, anhydrous, aprotic, hydrophobic, non-polar vehicles with low reactivity | DURECT CORPORATION | 2001-11-08 | — | — | US | disclosed |
| US-6264990-B1 | ACTIVE MATERIALS | ALZA CORPORATION | 2001-07-24 | — | — | US | disclosed |
| WO-2001037804-A2 | PRESERVATION AND FORMULATION OF BIOACTIVE MATERIALS | UNIVERSAL PRESERVATION TECHNOLOGIES, INC. (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-0939655-A1 | STABLE PROTEIN AND NUCLEIC ACID FORMULATIONS USING NON-AQUEOUS, ANHYDROUS, APROTIC, HYDROPHOBIC, NON-POLAR VEHICLES WITH LOW REACTIVITY | ALZA CORPORATION (US) | 1999-09-08 | — | — | EP | disclosed |
| WO-1998016250-A1 | STABLE PROTEIN AND NUCLEIC ACID FORMULATIONS USING NON-AQUEOUS, ANHYDROUS, APROTIC, HYDROPHOBIC, NON-POLAR VEHICLES WITH LOW REACTIVITY | ALZA CORPORATION (US) | 1998-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11505535-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | THRB 947/4885LMNA 774/4885CA2 1086/4885 |
| US-20230331691-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | THRB 947/4885LMNA 774/4885CA2 1086/4885 |
| US-12365663-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | THRB 947/4885LMNA 774/4885CA2 1086/4885 |
| US-11958822-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | THRB 947/4885LMNA 774/4885CA2 1086/4885 |
| US-11339139-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | THRB 947/4885LMNA 774/4885CA2 1086/4885 |
| US-20220112173-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | THRB 947/4885LMNA 774/4885CA2 1086/4885 |
| US-20240287018-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | THRB 947/4885LMNA 774/4885CA2 1086/4885 |
| US-11046666-B2 | Treprostinil derivative compounds and methods of using same | PTGIS, PTGIR, PTGER3 | THRB 947/4885LMNA 774/4885CA2 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.